Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview. Issue 1 (9th January 2021)

• Record Type: Journal Article
• Authors: Rezaee, Haleh; Pourkarim, Fariba; Pourtaghi‐Anvarian, Samira; Entezari‐Maleki, Taher; Asvadi‐Kermani, Touraj; Nouri‐Vaskeh, Masoud
• Is Part Of: Pharmacology research & perspectives. Volume 9:Issue 1(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-01-09
• Subjects: adverse reactions -- chloroquine -- COVID‐19 -- drug‐drug interaction -- Kaletra -- remdesivir; Pharmacology -- Periodicals; Drug development -- Periodicals; 615.105
• DOI: 10.1002/prp2.705
• Languages: English
• ISSNs: 2052-1707

Abstract

Abstract: Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT‐prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID‐19 in order to minimize the adverse reactions. Abstract : COVID‐19 is a life‐threatening illness with high prevalence. The use of non‐specific medications may increase the risk of drug‐drug interactions and side effects.